Europe's largest "green" methanol plant opened in Denmark on Tuesday, boosting the continent's emissions reduction efforts -- ...

Injected weight-loss drugs Wegovy, from Novo Nordisk, and Eli Lilly's Zepbound have U.S. list prices of over $1,000 a month.

The U.S. Centers for Medicare and Medicaid Services (CMS) said on Monday that it would announce a list of 15 drugs eligible ...

The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the ...

Lecanemab and donanemab (Kisunla), another anti-amyloid treatment, won approval based on evidence that they slowed cognitive ...

Novo Nordisk has potential with a 27% upside, strong market shares, and high ROI strategies. See why we recommend a buy on ...

For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is expected at 16-24% growth. However, this forecast, 3% lower for revenue and ...

With a late-stage trial win for its Norditropin heir in hand, Novo Nordisk is making good on plans to boost its profile in ...

We came across a bullish thesis on Novo Nordisk A/S (NVO) on Substack by Kontra Investments. In this article, we will summarize the bulls’ thesis on NVO.

Novo Nordisk A/S’s decision to stop making insulin pens will narrow treatment options for children with diabetes unless ...

While the drugs certainly contribute to weight loss and health gains, they also cause a decline in muscle that some doctors ...

The best metric is not weight, but a particularly toxic kind of fat.